{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:43:20Z","timestamp":1777502600819,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K10408"],"award-info":[{"award-number":["20K10408"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K06646"],"award-info":[{"award-number":["21K06646"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s40801-022-00324-4","type":"journal-article","created":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T19:29:05Z","timestamp":1659814145000},"page":"659-665","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Osteonecrosis of the Jaw Caused by Denosumab in Treatment-Na\u00efve and Pre-Treatment with Zoledronic Acid Groups: A Time-to-Onset Study Using the Japanese Adverse Drug Event Report (JADER) Database"],"prefix":"10.1007","volume":"9","author":[{"given":"Shiori","family":"Hasegawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Ikesue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riko","family":"Satake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misaki","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoka","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Oura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Muroi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Hashida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Iguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5062-5522","authenticated-orcid":false,"given":"Mitsuhiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,6]]},"reference":[{"key":"324_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ctrv.2018.06.007","volume":"69","author":"S Otto","year":"2018","unstructured":"Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schi\u00f8dt M. Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev. 2018;69:177\u201387. https:\/\/doi.org\/10.1016\/j.ctrv.2018.06.007.","journal-title":"Cancer Treat Rev"},{"key":"324_CR2","doi-asserted-by":"publisher","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:6243s-s6249. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0931.","journal-title":"Clin Cancer Res"},{"key":"324_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016022","volume":"7","author":"E Svensson","year":"2017","unstructured":"Svensson E, Christiansen CF, Ulrichsen SP, R\u00f8rth MR, S\u00f8rensen HT. Survival after bone metastasis by primary cancer type: a Danish population-based cohort study. BMJ Open. 2017;7: e016022. https:\/\/doi.org\/10.1136\/bmjopen-2017-016022.","journal-title":"BMJ Open"},{"key":"324_CR4","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, De Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28:5132\u20139. https:\/\/doi.org\/10.1200\/JCO.2010.29.7101.","journal-title":"J Clin Oncol"},{"key":"324_CR5","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29:1125\u201332. https:\/\/doi.org\/10.1200\/JCO.2010.31.3304.","journal-title":"J Clin Oncol"},{"key":"324_CR6","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Dami\u00e3o R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377:813\u201322. https:\/\/doi.org\/10.1016\/S0140-6736(10)62344-6.","journal-title":"Lancet"},{"key":"324_CR7","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.14219\/JADA.ARCHIVE.2005.0108","volume":"136","author":"CA Migliorati","year":"2005","unstructured":"Migliorati CA, Casiglia J, Epstein J, Jacobsem PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc. 2005;136:1658\u201368. https:\/\/doi.org\/10.14219\/JADA.ARCHIVE.2005.0108.","journal-title":"J Am Dent Assoc"},{"key":"324_CR8","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1210\/JC.2005-0057","volume":"90","author":"SM Ott","year":"2005","unstructured":"Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab. 2005;90:1897\u20139. https:\/\/doi.org\/10.1210\/JC.2005-0057.","journal-title":"J Clin Endocrinol Metab"},{"key":"324_CR9","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","volume":"48","author":"R Baron","year":"2011","unstructured":"Baron R, Ferrari S, Russell RGG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48:677\u201392. https:\/\/doi.org\/10.1016\/j.bone.2010.11.020.","journal-title":"Bone"},{"key":"324_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00774-016-0810-7","volume":"35","author":"T Yoneda","year":"2017","unstructured":"Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, et al. Antiresorptive agent-related osteonecrosis of the jaw: position paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab. 2017;35:1\u201314. https:\/\/doi.org\/10.1007\/s00774-016-0810-7.","journal-title":"J Bone Miner Metab"},{"key":"324_CR11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrd3705","volume":"11","author":"DL Lacey","year":"2012","unstructured":"Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012;11:401\u201319. https:\/\/doi.org\/10.1038\/nrd3705.","journal-title":"Nat Rev Drug Discov"},{"key":"324_CR12","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115\u20137. https:\/\/doi.org\/10.1016\/S0278-2391(03)00720-1.","journal-title":"J Oral Maxillofac Surg"},{"key":"324_CR13","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","volume":"23","author":"F Saad","year":"2012","unstructured":"Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw:iIntegrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23:1341\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdr435.","journal-title":"Ann Oncol"},{"key":"324_CR14","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00520-015-2904-5","volume":"24","author":"AT Stopeck","year":"2016","unstructured":"Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, et al. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer. 2016;24:447\u201355. https:\/\/doi.org\/10.1007\/s00520-015-2904-5.","journal-title":"Support Care Cancer"},{"key":"324_CR15","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1002\/CNCR.33802","volume":"127","author":"V Ehrenstein","year":"2021","unstructured":"Ehrenstein V, Heide-J\u00f8rgensen U, Schi\u00f8dt M, Akre O, Herlofson BB, Hansen S, et al. Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: results of a regulator-mandated cohort postauthorization safety study in Denmark, Norway, and Sweden. Cancer. 2021;127:4050\u20138. https:\/\/doi.org\/10.1002\/CNCR.33802.","journal-title":"Cancer"},{"key":"324_CR16","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.oooo.2018.02.010","volume":"125","author":"T Higuchi","year":"2018","unstructured":"Higuchi T, Soga Y, Muro M, Kajizono M, Kitamura Y, Sendo T, et al. Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125:547\u201351. https:\/\/doi.org\/10.1016\/j.oooo.2018.02.010.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"324_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00280-021-04262-w","volume":"87","author":"H Ikesue","year":"2021","unstructured":"Ikesue H, Doi K, Morimoto M, Hirabatake M, Muroi N, Yamamoto S, et al. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases. Cancer Chemother Pharmacol. 2021;87:1\u20137. https:\/\/doi.org\/10.1007\/s00280-021-04262-w.","journal-title":"Cancer Chemother Pharmacol"},{"key":"324_CR18","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/BIB\/BBX010","volume":"19","author":"S Vilar","year":"2018","unstructured":"Vilar S, Friedman C, Hripcsak G. Detection of drug\u2013drug interactions through data mining studies using clinical sources, scientific literature and social media. Brief Bioinform. 2018;19:863\u201377. https:\/\/doi.org\/10.1093\/BIB\/BBX010.","journal-title":"Brief Bioinform"},{"key":"324_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/TCRM.S176620","volume":"15","author":"A Inada","year":"2018","unstructured":"Inada A, Hosohata K, Oyama S, Niinomi I, Mori Y, Yamaguchi Y, et al. Evaluation of medication-related osteonecrosis of the jaw using the Japanese Adverse Drug Event Report database. Ther Clin Risk Manag. 2018;15:59\u201364. https:\/\/doi.org\/10.2147\/TCRM.S176620.","journal-title":"Ther Clin Risk Manag"},{"key":"324_CR20","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3390\/ph13120467","volume":"13","author":"S Toriumi","year":"2020","unstructured":"Toriumi S, Kobayashi A, Uesawa Y. Comprehensive study of the risk factors for medication-related osteonecrosis of the jaw based on the Japanese Adverse Drug Event Report database. Pharmaceuticals. 2020;13:467. https:\/\/doi.org\/10.3390\/ph13120467.","journal-title":"Pharmaceuticals"},{"key":"324_CR21","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/jbmr.2693","volume":"31","author":"X Zhang","year":"2016","unstructured":"Zhang X, Hamadeh IS, Song S, Katz J, Moreb JS, Langaee TY, et al. Osteonecrosis of the jaw in the United States Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS). J Bone Miner Res. 2016;31:336\u201340. https:\/\/doi.org\/10.1002\/jbmr.2693.","journal-title":"J Bone Miner Res"},{"key":"324_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40780-015-0035-2","volume":"1","author":"M Nakamura","year":"2015","unstructured":"Nakamura M, Umetsu R, Abe J, Matsui T, Ueda N, Kato Y, et al. Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events. J Pharm Health Care Sci. 2015;1:34. https:\/\/doi.org\/10.1186\/s40780-015-0035-2.","journal-title":"J Pharm Health Care Sci."},{"key":"324_CR23","unstructured":"Ranmark subcutaneous injection. Package insert. https:\/\/www.medicallibrary-dsc.info\/di\/ranmark_subcutaneous_injection_120mg\/pdf\/pi_rmk_2107.pdf. Accessed 5 Jul 2022."},{"key":"324_CR24","unstructured":"Pralia subcutaneous injection. Package insert. https:\/\/www.medicallibrary-dsc.info\/di\/pralia_subcutaneous_injection_syringe_60mg\/pdf\/pi_prl_2107.pdf. Accessed 5 Jul 2022."},{"key":"324_CR25","unstructured":"Xgeva prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125320s094lbl.pdf. Accessed 5 Jul 2022."},{"key":"324_CR26","unstructured":"Prolia prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125320s5s6lbl.pdf. Accessed 5 Jul 2022."},{"key":"324_CR27","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","volume":"36","author":"O Sauzet","year":"2013","unstructured":"Sauzet O, Carvajal A, Escudero A, Molokhia M, Cornelius VR. Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data. Drug Saf. 2013;36:995\u20131006. https:\/\/doi.org\/10.1007\/s40264-013-0061-7.","journal-title":"Drug Saf"},{"key":"324_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40780-017-0088-5","volume":"3","author":"H Hatahira","year":"2017","unstructured":"Hatahira H, Abe J, Hane Y, Matsui T, Sasaoka S, Motooka Y, et al. Drug-induced gingival hyperplasia: a retrospective study using spontaneous reporting system databases. J Pharm Health Care Sci. 2017;3:19. https:\/\/doi.org\/10.1186\/s40780-017-0088-5.","journal-title":"J Pharm Health Care Sci."},{"key":"324_CR29","doi-asserted-by":"publisher","first-page":"326","DOI":"10.4317\/medoral.23324","volume":"25","author":"A Limones","year":"2020","unstructured":"Limones A, Miguel S\u00e1ez-Alcaide L, Angulo D\u00edaz-Parre\u00f1o S, Helm A, Bornstein MM, Molinero-Mourelle P. Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab vs zoledronic acid: a systematic review and meta-analysis. Oral Med Pathol. 2020;25:326\u201362. https:\/\/doi.org\/10.4317\/medoral.23324.","journal-title":"Oral Med Pathol."},{"key":"324_CR30","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/jop.12646","volume":"47","author":"C Egloff-Juras","year":"2018","unstructured":"Egloff-Juras C, Gallois A, Salleron J, Massard V, Dolivet G, Guillet J, et al. Denosumab-related osteonecrosis of the jaw: a retrospective study. J Oral Pathol Med. 2018;47:66\u201370. https:\/\/doi.org\/10.1111\/jop.12646.","journal-title":"J Oral Pathol Med"},{"key":"324_CR31","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1080\/17843286.2017.1348001","volume":"73","author":"T Loyson","year":"2018","unstructured":"Loyson T, Van Cann T, Sch\u00f6ffski P, Clement PM, Bechter O, Spriet I, et al. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab. Acta Clin Belgica Int J Clin Lab Med. 2018;73:100\u20139. https:\/\/doi.org\/10.1080\/17843286.2017.1348001.","journal-title":"Acta Clin Belgica Int J Clin Lab Med."},{"key":"324_CR32","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1200\/JCO.19.01186","volume":"37","author":"N Yarom","year":"2019","unstructured":"Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, et al. Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline. J Clin Oncol. 2019;37:2270\u201390. https:\/\/doi.org\/10.1200\/JCO.19.01186.","journal-title":"J Clin Oncol"},{"key":"324_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11:3\u201310. https:\/\/doi.org\/10.1002\/pds.668.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"324_CR34","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1002\/SIM.3557","volume":"28","author":"BL Egleston","year":"2009","unstructured":"Egleston BL, Wong YN. Sensitivity analysis to investigate the impact of a missing covariate on survival analyses using cancer registry data. Stat Med. 2009;28:1498. https:\/\/doi.org\/10.1002\/SIM.3557.","journal-title":"Stat Med"},{"key":"324_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-13-92","volume":"13","author":"L Thabane","year":"2013","unstructured":"Thabane L, Mbuagbaw L, Zhang S, Samaan Z, Marcucci M, Ye C, et al. A tutorial on sensitivity analyses in clinical trials: the what, why, when and how. BMC Med Res Methodol. 2013;13:1\u201312. https:\/\/doi.org\/10.1186\/1471-2288-13-92.","journal-title":"BMC Med Res Methodol"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-022-00324-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-022-00324-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-022-00324-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T19:33:24Z","timestamp":1669836804000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-022-00324-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,6]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["324"],"URL":"https:\/\/doi.org\/10.1007\/s40801-022-00324-4","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,6]]},"assertion":[{"value":"20 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was partially supported by the Japan Society for the Promotion of Science KAKENHI (grant numbers 20K10408, 21K06646). No additional external funding was received for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"SH is an employee of Kaneichi Pharmaceutical. Co. Ltd. The other authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}},{"value":"Ethics approval was not sought because this was an observational study without any research subjects. All results were obtained from data openly available online from the website of the PMDA (). All data from the JADER database were fully anonymized by the regulatory authority before we accessed them.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Our research does not fall within the purview of any of the following laws and guidelines: \u201cClinical Trials Act (Act No. 16 of April 14, 2017)\u201d, \u201cAct on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (Law number: Act No. 145 of 1960, Last Version: Amendment of Act No. 50 of 2015)\u201d, \u201cGuideline for good clinical practice E6 (R1), \u201d, \u201cEthical guidelines for human genome and gene analysis research, \u201d, and \u201cEthical Guidelines for Medical and Health Research Involving Human Subjects, \u201d. The study is not subject to ethical examination as the study was an observational study without any research subjects. No consent to participate was required owing to the retrospective nature of this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"No administrative permissions or licenses were required to access the raw data from the Japanese Adverse Drug Event Report database because all results were obtained from data openly available online from the PMDA website. All data from the JADER database were fully anonymized by the regulatory authority before we accessed them.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data generated or analyzed during this study are included in this published article and its supplementary information files.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"SH, HI, and MN contributed to the overall concept and design of the study. SH, HI, and MN wrote the main manuscript text. SH, RS, MU, and YY carried out the data extraction and statistical analysis. MT, KM, WW, and KO contributed to the data validation process. NM, TH, and KI revised the article critically for important intellectual content. All authors have reviewed the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}